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ABSTRACT
Tissue grafts are the gold standard for replacing large volume tissue defects. Yet, they present
several risks, including infection, low functional outcomes, and reduced graft integrity. Tissue
engineering (TE) combines cells and biomaterial scaffolds to foster tissue growth and remodeling.
Bone marrow stromal cells (BMSCs) have been shown to respond to the stiffness of their
microenvironment, resulting in differentiation into different lineages. 3D porous chitosan-alginate
(CA) scaffolds have been previously demonstrated for bone TE with osteoblasts and BMSCs;
however, only a single scaffold composition (4 wt%) was studied. Three CA scaffold compositions
(2, 4, 6 wt% CA) were produced. Scanning electron microscopy images were obtained to
determine average pore sizes for 2, 4, and 6 wt% CA scaffolds, which were 233, 208, and 146 µm.
Compression testing was performed on CA scaffolds in dry and wet conditions, where higher
concentrations yielded higher stiffnesses ranging from 0.22 to 5.34 kPa and 21.1 to 47.3 Pa,
respectively. Fourier transform infrared spectroscopy performed on the CA scaffolds confirmed
polyelectrolyte complex formation for all compositions. Human BMSCs from three donors were
seeded on CA scaffolds, cultured in growth media for 14 days, then cultured in adipogenic or
osteogenic differentiation media for 28 days to promote differentiation. Our hypothesis was that
scaffold stiffness would influence BMSC differentiation, with softer scaffolds promoting
adipogenesis and stiffer scaffolds promoting osteogenesis. BMSCs formed multicellular spheroids
in all CA scaffold concentrations, while the 2 wt% CA scaffolds had smaller spheroids compared
to the 4 wt% and 6 wt% CA scaffolds. Osteogenic and adipogenic differentiation were evaluated
with Alizarin Red and Oil Red O staining, respectively. While positive staining was observed in
all scaffold compositions, more robust differentiation was expected, thereby disproving our
iii

hypothesis. The polysaccharide composition of the CA scaffolds likely contributed to the spheroid
formation and limited differentiation.
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CHAPTER 1: INTRODUCTION
Large volume tissue defects caused by trauma, congenital defects, or disease present a great
challenge for reconstructive surgeons. While traditional tissue grafts such as allografts and
autografts present viable alternatives, there are also many drawbacks associated with them. These
types of treatments are an insufficient solution due to their high risk of infection, lack of
availability, and poor functional outcome. Tissue engineering is an interdisciplinary field that aims
to develop solutions that can help enhance, replace, or restore damaged tissues. The main approach
of tissue engineering is to combine cells and biomaterials to develop functional tissues that can be
implanted at the site of injury in a patient.
A common approach is to use BMSCs (bone marrow stromal cells) and biomaterial
scaffolds resulting in increased osteogenesis in model systems in vitro. It has also been shown that
BMSCs are responsive to the stiffness of their microenvironment. Therefore, it is of great
importance to better understand cell-material interactions, specifically concerning BMSC
microenvironment stiffness and lineage differentiation, in order to move the tissue engineering
field forward. Chitosan Alginate (CA) scaffolds have been previously demonstrated for bone tissue
engineering applications with osteoblasts and BMSCs [1, 2]. Yet, only a single CA composition
(4 wt%) has been studied. This thesis examines the effects of CA scaffold stiffness variations (2,
4, 6 wt%) on the differentiation of three BMSC donors. Understanding BMSC donor variation is
an important step towards the ultimate goal of TE, which is to develop biomaterials that have
specific regenerative effects in a large patient population.
The first chapter includes a literature review that covers essential topics in the field starting
with the clinical need, tissue engineering, and biomaterials for tissue engineering, including a
1

section on CA scaffolds. The second chapter is the methodology section which includes a
description of the CA scaffolds synthesis, materials characterization, cell culture, and cellular
analysis. The third chapter presents the results from the scaffold characterization and cell culture
studies, including SEM, mechanical testing, FTIR, cell proliferation assays, cell proliferation
imaging, and differentiation staining. The fourth chapter covers the discussion and conclusions
upon which the relationship between CA scaffold stiffness and BMSC differentiation is elucidated.
Variations in BMSC donor morphology and differentiation are also discussed.
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CHAPTER 2: LITERATURE REVIEW
Clinical Need
Surgical reconstruction of tissue defects is one of today’s biggest healthcare challenges and
expenditures. When tissue defects are large enough that the body can’t heal them on its own, tissue
grafts are surgically implanted into the defect site. These types of injuries are called “critical-sized
defects” and occur when the non-regenerative threshold of bone tissue has been reached [3]. The
2017 U.S. average estimated cost of all organ transplants was $2.26 billion for people under age
65 and $625 million for people over age 65 [2]. Autografts, which are tissue or organ transplants
from one part of a person to another location in the same person, are often considered the “gold
standard” for replacing diseased or damaged tissues. Yet, they present several risks including
donor site morbidity, infection, low functional and cosmetic outcome, and reduced graft integrity
[5]. Allografts, which are tissue or organ transplants from another person, remove the complication
of donor site morbidity. However, they can occasionally trigger an immunogenic response which
requires recipients to be placed on immunosuppressant drugs to prevent rejection [6]. Additionally,
allografts are typically frozen, irradiated and/or lyophilized to reduce the likelihood of disease
transmission, which can compromise their mechanical integrity and reduce bioactivity. Therefore,
while allografts are a viable tissue replacement alternative, they still carry many of the risks
associated with autografts. Additionally, both autografts and allografts have a limited supply that
can fail to meet the needs of larger defects.
In order to overcome the issues associated with tissue and organ grafts, scientists and
engineers are developing innovative biomaterials to repair or replace damaged tissues. The
biomaterials field is highly multidisciplinary and it studies materials with a special focus on their
interaction with the biological environment for primarily medical purposes, such as therapeutic or
3

diagnostic applications [7]. The biology of host-material interactions strongly determines the
biocompatibility of a material. Biocompatibility is defined as the ability of a biomaterial to
generate an appropriate host response within its application, which includes resistance to blood
clotting, resistance to bacterial colonization, and regular healing [3, 4]. Besides their enhanced
biocompatibility and increased supply, biomaterials can also be designed to fit the specific tissue
graft needs of a patient. Therefore, as the rates of chronic disease and the aging population continue
to increase, the human impact and commercial market size for the biomaterials field are projected
to expand.
Tissue Engineering
Tissue engineering is a branch of biomedical engineering that focuses on the design and
fabrication of biomaterials to repair or replace damaged tissues and organs by developing
substitutes or reconstructing them as an alternative to conventional tissue grafts. The tissue
engineering field is highly interdisciplinary as it requires the collaboration of materials scientists,
cell biologists, chemists, and engineers. The main strategy is to combine cells and biomaterials
that are used to grow or foster the remodeling of tissues and organs [9]. As can be observed in
Figure 1, cells can be harvested from a patient (1), expanded through cell culture in vitro (2),
seeded into a biomaterial (3), cultured for proliferation (4), and finally implanted at the site of
injury in a patient (5).
Three-dimensional (3D) biomaterials recreate the extracellular matrix (ECM) environment
and provide mechanical support for newly formed tissues [10]. 3D biomaterials can take different
forms, such as nanofiber scaffolds, hydrogels, and 3D porous sponges, among others. Scaffolds
are porous biomaterials that (i) promote cell-material interactions and ECM deposition, (ii) allow
sufficient gas, nutrient, and growth factor transport for cell survival, proliferation, and
4

differentiation, (iii) degrade at a controlled rate that matches that of native tissue, (iv) cause
minimal inflammation or in vivo cytotoxicity [11]. The 3D scaffold also allows for cell migration
and proliferation followed by the secretion of native ECM, which can lead to a complete and
natural long term tissue replacement [12].

Figure 1. Diagram of the classical tissue engineering model. Cells are harvested from a patient (1),
expanded in vitro (2), cultured within a biomaterial scaffold (3-4), and implanted at the site of injury (5).

A common approach in tissue engineering involves harvesting primary stem cells from a
patient and culturing them in vitro in a 3D scaffold (Figure 2a). Cultures within scaffolds can be
grown in a static (incubator) or a dynamic (bioreactor) environment. After cells proliferate and
differentiate into specific tissues, the tissue engineered constructs are implanted at the site of injury
to help regenerate damaged tissues. A second approach involves implanting or injecting the 3D
scaffolds in vivo and allowing tissue formation and ingrowth to occur in situ (Figure 2b). In this
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case, scaffolds are implanted without cells and the patient is used as an incubator to grow the tissue
or organ, where cells in the surrounding tissue spontaneously populate the scaffold.

Figure 2. Two main approaches to tissue engineering: (A) Transplantation of in vitro grown tissues and
(B) Promotion of tissue regeneration in situ [8].

Biomaterials can be biocompatible, bioactive, and biodegradable depending on their
specific application. For example, a hip implant ideally would not be biodegradable in order to
provide long term mechanical support, while a skin graft would ideally degrade at a rate matching
the regenerating tissue. Biocompatibility prevents an adverse immune response from the patient,
bioactivity stimulates cell regeneration, and biodegradation accommodates neo-tissue formation.
The scaffold stiffness is typically chosen to match that of the target native tissue and is sufficient
to withstand long-term culture and implantation. The main challenges preventing the clinical
translation of these products include achieving sufficient biological function from cellularized
constructs, optimal host biocompatibility, and cost reduction [13]. It is expected that advances in
stem cells, biomaterials, biofabrication, and immunomodulation will speed the clinical application
of tissue engineering products by tackling these challenges.

6

Bone Marrow Stromal Cells in Tissue Engineering
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that have the potential to
differentiate into different end-stage mesenchymal cell types, including bone, cartilage, muscle,
bone marrow stroma, tendon/ligament, fat, dermis, and other connective tissues, as can be
observed in Figure 3 [14]. MSCs reside in a variety of tissues and have the ability to regenerate
cell types of the previously mentioned tissues. One type of MSCs, bone marrow stromal cells
(BMSCs) are non-hematopoietic adherent cells, a subset of which are skeletal stem cells (SSCs)
that can form cartilage, bone, hematopoiesis-supportive stroma, and marrow adipocytes [15].
Besides being undifferentiated, BMSCs have significant self-renewal capacities. Therefore, these
cells are very useful in the practices of bone tissue engineering and regenerative medicine.

Figure 3. Flowchart of MSC possible commitment, lineage progression, and maturation [16].
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One of the most common ways to obtain BMSCs is through bone marrow aspirate from
the iliac crest which is considered to be one of its most accessible and enriched sources.
Alternatively, adipose derived stromal cells (ADSCs) can be derived from adipose tissue and
resemble BMSCs in morphology, phenotype, and differentiation capacity [17]. Both BMSCs and
ADCSs have finite life spans despite advancements in long term culture expansion. This occurs
since they undergo telomere shortening after each division cycle, which results in gradual
senescence [18]. BMSCs were found to decrease in adipogenic potential after 7 passages, with 1
in 2035 cells being capable of differentiating into an adipocyte at passage 7 [19]. BMSCs were
found to MSCs play a significant role in development, as well as adult tissue repair.
BMSCs for Bone Tissue Engineering
The osteogenic induction of BMSCs is a highly programmed process that has been
extensively studied in vitro and stimulates osteoblast formation. Osteoblasts are relevant cells for
bone tissue engineering since they are in charge of secreting unmineralized, collagen-rich osteoids,
upon which bone mineralization occurs [20]. The synthetic glucocorticoid dexamethasone (DEX)
stimulates MSC proliferation and osteogenic differentiation [21]. Organic phosphates like glycerolphosphate (BGP) enhance osteogenesis by supporting the mineralization and modulation
of osteoblast activity [22]. Additionally, free phosphate groups induce the mRNA and protein
expression of osteopontin, as well as influence the production and nuclear export of the osteogenic
regulatory gene Cbfa1 (core binding factor alpha 1) [28, 29]. Supplements such as L-ascorbic acid
(LAA) are also commonly used for osteogenic induction.
The osteogenic differentiation of BMSCs can be confirmed by different bone matrix
molecules, mineral crystals, and nodules. An early indicator of BMSC osteogenic differentiation
8

is the upregulation of alkaline phosphatase activity. Additionally, the presence of mineralized
BMSC matrix can be verified with von Kossa or Alizarin Red stains [25]. Osteocalcin, osteopontin,
and osteonectin are non-collagenous proteins found in the bone matrix and late osteogenic
differentiation markers that can be measured using RT-PCR or proteomically using ELISA [25].
Many natural and synthetic biomaterials have shown promise as carriers for MSC delivery in
orthopedic therapeutic applications such as polysaccharides (chitosan, alginate, or hyaluronic acid)
PCL, PLA, and PLGA [26]. Advances in the biomaterials field have led to a transition from inert,
non-porous materials to highly porous, osteoconductive, cell-matrix composite materials.
BMSCs for Adipose Tissue Engineering
A large proportion of surgical procedures performed each year are to repair soft tissue
defects resulting from a loss of adipose tissue. Therefore, the field of adipose tissue engineering is
necessary in these cases. Adipogenic induction of BMSCs is a complex process that is controlled
by steroid hormones, transcription factors, and secreted cytokines/adipokines [27]. BMSC
adipogenic induction yields adipocytes which are characterized by lipid droplet formation [28].
Bone marrow adipocytes are thought to differentiate from BMSCs in vitro and in vivo. In vitro
induction of BMSCs requires specific media supplementations. Adipogenic medium for
differentiation usually includes dexamethasone (DEX), 3-isobutyl-1-methylxanthine (IBMX), and
indomethacin (IM) [14]. Indomethacin is an anti-inflammatory drug that binds to and activates the
transcription factor peroxisome receptor gamma (PPAR-).
One of the most important factors in BMSC adipogenic differentiation in PPAR-2, which
can be detected through RT-PCR [25]. Additionally, Oil Red O is a stain that binds to lipid
vacuoles synthesized intracellularly by BMSC-derived adipogenic cells. Common adipogenic
9

gene products, such as lipoprotein lipase (LPL) and polyclonal antibody anti-P2, can be amplified
and detected through RT-PCR [29]. Adipose tissue accumulates lipid vacuoles intracellularly and
the extracellular matrix consists of interstitial fibrous tissue, nerve supplies, and vascular
lymphatic network [25]. Both synthetic polymers (i.e. PLA, PLGA, PEG) and natural polymers
(i.e. collagen, fibrin, gelatin) have been explored for adipose tissue engineering applications with
considerable differences in material biocompatibility, mechanical and chemical properties.
Collagen is one of the most prevalent natural polymers used for adipose tissue engineering due to
its natural prevalence in native adipose ECM, which allows it to promote favorable adipose
outcomes [30]. Other natural polymers used in adipose tissue engineering include adipose-derived
ECM, decellularized human placenta, hyaluronan, and matrigel.
Mechanotransduction
Stem cell maintenance and differentiation are influenced by different aspects of their
microenvironment, including matrix structure, chemistry, and stiffness. ECM proteins have unique
distributions and assembly patterns in different tissues which contribute to developmental
processes, since the initiation of matrix expression precedes the generation of pluripotent
embryonic stem cells (ESCs) and the onset of cell movement [31]. Additionally, fibronectin
regulates cell migration during gastrulation, which occurs as stem cell fate is being established
[31]. While ESCs have a temporally changing matrix that may be linked to differentiation, MSCs
are known to actively migrate to tissues with different matrix compositions [29]. Therefore, the
influence of matrix variations towards MSC differentiation is worth examining.
Cells can actively sense their environment and respond to matrix physical and chemical
cues through focal adhesions. Focal adhesions are large protein assembly complexes that
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physically couple the ECM to the intracellular actin cytoskeleton [32]. Integrins, the major
adhesion receptors, are heterodimers comprised of  and  subunits that have high binding affinity
for specific ECM proteins and assemble to link the extracellular and intracellular environments
[33]. Additionally, integrins allow for bidirectional outside-in and inside-out force transfer and
signal transmission [34]. As cells first secrete matrix proteins in vivo, integrins rearrange these
molecules [35]. Adapter proteins, such as talin and viculin, connect integrins to the actin
cytoskeleton, which is in turn connected to the nucleus as can be observed in Figure 4 [32].
Therefore, integrins are vital surface transmembrane receptors that can also mediate focal adhesion
assembly, cytoskeletal organization, and a cascade of downstream signal transduction events that
ultimately regulate gene expression and cell behavior [34].

Figure 4. Mechanical forces applied to cells are transmitted across integrin receptors into cytoplasmic
domains. Forces concentrated in the focal adhesions stimulate clustering of dimeric (,) integrin
receptors and of focal adhesion proteins, such as Vinculin (Vin), Paxillin (Pax), and Talin (Tal) [8].
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Cells can sense their microenvironment stiffness by pulling against the ECM and assessing
its resistance to deformation through focal adhesions. The resistance that a cell feels as it pulls on
the ECM is the matrix elastic constant or stiffness, which varies widely across different tissues
types. For example, the matrix elastic constant in collagenous bone (100 kPa) is a lot higher than
in muscle (10 kPa) and brain (1 kPa) tissues [36]. Cells also alter matrix mechanics by exerting
different forces on the ECM, thereby establishing a feedback loop that can influence cell fate and
function [32]. This dynamic process of cell-ECM mechanical interactions is called
mechanotransduction. These interactions are mediated by integrin proteins within focal adhesion
complexes that transmit mechanical forces across the cell surface. Cells exert these cytoskeletongenerated contractile forces through the same integrin-ECM bonds that help them sense matrix
stiffness [37]. Focal adhesions are therefore key elements for mechanotransduction, as they bear
high mechanical loads and even contain signaling molecules that change their activity under
mechanical stress [38]. Forces concentrated within focal adhesions stimulate clustering of dimeric
integrin proteins and recruitment of focal adhesion proteins (i.e. talin, vinulin, paxillin) as can be
observed in Figure 5 [34].
Biomaterial structure can also strongly influence how a cell senses its microenvironment.
For example, when a polymer foam material has pore sizes that are much greater than the cell size,
a relatively flat or slightly curved substrate material is effectively presented to the cell as it adheres
to a strut. In this case, the basal surface of a cell will attach to the material, which induces a
response similar to those observed on planar substrates where high cellular forces occur on stiff
materials [32]. On the other hand, smaller pore sizes allow the cell to attach to the material in all
dimensions and yield smaller forces than those observed on planar substrates [31]. Yet, it is
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important to note that cell-material interactions are fast changing, and that the matrix synthesized
by a cell can become a relevant variable to guide cell fate at later timepoints. Besides the stiffness,
cells are also exposed to mechanical forces from fluid flow and matrix strain which stimulate
differentiation by enhancing cell adhesion, cytoskeleton stiffness, and mechanotransductive
signaling.

Figure 5. Cells present a small spreading area on soft matrices, associated with poorly defined
cytoskeleton, detachment of focal adhesion complexes, and integrin uptake. On substrates with medium
stiffness, cells develop elongated focal adhesions and well aligned stress fibers. On rigid matrices, cells
display a large spreading area, prominent stress fibers, and enhanced focal adhesion assembly [34].

Cells can also obtain cues regarding matrix chemistry through the specific subset of
integrins that interacts with the matrix. Additionally, the presence of certain ECM proteins can
influence cell adhesion and differentiation [39]. This occurs through ligand conformational
changes that enhance force transmission to integrins on the surface of the cell [40]. Regional
differences in receptor-ligand distribution have been shown to control MSC osteogenic
differentiation [39]. Matrix chemistry can also be altered by using recombinant proteins that
contain adhesion molecules, such as RGD peptides. Even variation in reactive surface groups, such
as methyl versus carboxyl, can alter cell adhesion and induce change between self-renewal and
13

differentiation [41]. Matrix adhesion enhancements, through surface coatings and crosslinking can
also improve cell adhesion to matrices and possibly alter integrin expression as well as cell
differentiation [42]. Other cell types, besides stem cells, are also responsive to differences in
adhesive ligand concentrations, such as malignant phenotypes in mammary epithelial cells that are
induced by high levels of fibronectin [43]. Growth factors can also become sequestered within the
ECM to be later released by proteolytic degradation or by cell-generated forces [44].
Biomaterials for Tissue Engineering
A variety of factors influence the material selection for a tissue engineering application,
such as biocompatibility, surface chemistry, molecular weight, microstructure, degradability,
processability, and mechanical properties [45]. Biomaterials used for tissue repair include metals,
ceramics, and polymers. Metal based biomaterials are good for load bearing applications due to
their high mechanical properties and resistance to wear and shock. Ceramic based biomaterials are
mostly bioinert, have high elastic moduli, and compression resistance. Polymer based scaffolds
have unique properties such as high surface to volume ratio, high interconnected porosity,
controlled degradation, and tunable mechanical properties [11]. Additionally, polymers and their
degradation products usually have lower toxicity and better resemble natural ECM. Therefore,
polymer biomaterials have been widely used for the fabrication of medical devices and scaffolds
for tissue engineering. Researchers have attempted to grow a variety of tissues on polymer based
scaffolds, such as skin [46], bone [47], liver [48], heart grafts [49], pancreas [50], bladder [51],
corneas [52], and other soft tissues. Polymer based biomaterials can be natural or synthetic and
degradable or non-degradable according to their intended use. The final properties of the polymer
scaffold are dependent on its composition, structure, and macromolecular arrangement [11].
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Synthetic Polymers
Synthetic biomaterials are advantageous for tissue engineering applications due to their
simple processability into specific shapes and structures, high control of mechanical strength and
degradation kinetics, lack of immunogenicity, as well as easy post-modification for specific
applications [53]. Additionally, synthetic polymers are usually cheaper than natural materials and
can be uniformly fabricated in large quantities with a long shelf time [54]. Generally, synthetic
polymers have reproducible and predictable mechanical and physical properties, such as elastic
modulus and degradation kinetics, that ease their scale-up and manufacture [11]. While synthetic
polymers have great advantages due to the easy tunability of their mechanical properties and
degradation kinetics, they also present some drawbacks such as poor biocompatibility, release of
acidic degradation products, and rapid loss of mechanical properties [55]. Unfavorable byproducts
can obstruct tissue regeneration and even result in inflammation or fibrous encapsulation [55].
Additionally, they lack biological cues which can impede cellular adhesion and interaction [56].
A way to overcome this challenge is to modify synthetic polymers with bioactive molecules.
Some of the most commonly used synthetic polymers in tissue engineering include
polyesters such as polylactic acid (PLA), polyglycolic acid (PGA), and their copolymer polylacticco-glycolic acid (PLGA). These polymers have been widely used for tissue engineering due to
their high biodegradability through the hydrolysis of ester bonds, minimal inflammatory response,
and highly controlled degradation [57]. PLA has one additional methyl group than PGA in its
repeating unit which makes it more hydrophobic and reduces its hydrolysis rate. PLA scaffolds
can take months or years to lose their mechanical integrity both in vitro and in vivo [58]. PGA has
a relatively hydrophilic nature which causes its rapid degradation in aqueous solutions and in vivo,
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ultimately compromising its mechanical integrity within two to four weeks [22]. In order to
achieve intermediate degradation rates, PLGA with different lactic to glycolic acid ratios can be
synthesized.
Natural Polymers
Natural polymers were the first materials to have been used medically, since ancient
Egyptians used animal tendons as sutures [59]. Due to their bioactive nature, natural polymers
have often superior cell-material interactions which enhance their performance within a biological
system [11]. Additionally, they are biodegradable, biocompatible, and similar to the ECM. Their
main drawbacks include batch to batch variability, lower control of mechanical properties, and
limited processability. The two main classes of natural polymers used for tissue engineering
applications are proteins and polysaccharides.
Proteins include silk, collagen, fibrin, gelatin, elastin, and keratin, among others. The main
motivation for using protein based polymers is that they mimic proteins in the ECM, thereby
having the ability to direct cell migration, growth and organization during tissue regeneration.
Collagen has 28 different identified types, but type I is the most common in the human body.
Collagen is also a major component of the fibrillar extracellular matrix and it provides essential
signals for cell regulation, anchorage, migration and proliferation [60]. As a result it has been
studied for artificial skin (collagen IV), bone (collagen I), and cartilage (collagen II), resulting in
many tissue engineering products [61].
Gelatin is a natural polymer derived from collagen that is known for its biodegradability
and biocompatibility within the physiological environment. More specifically, gelatin is obtained
by acid and alkaline processing of collagen. Additionally, gelatin is a good carrier of bioactive
16

molecules, such as fibroblast growth factor, and has low immunogenicity [62], [63]. Gelatin has
been

widely

used

for

tissue

engineering

applications,

such

as

in

chitosan-

gelatin/nanohydroxyapatite composite scaffolds for bone tissue engineering [64]. Silk is a protein
polymer that is spun into fibers by lepidoptera larvae, such as silkworms, spiders, etc. Silk has
received great attention due to its high strength to weight ratio and slow degradation [65]. Silk
fibroin, a natural polymer made by silkworms that can be mass produced, is commonly used as a
textile fiber and for surgical sutures in the medical field [66]. Additionally, silk fibroin has been
successfully investigated for the tissue engineering of bone, cartilage, and ligaments [67].
Fibrin is a matrix protein made from the fibrinogen precursor, which self-polymerizes in
presence of the enzyme thrombin that triggers a coagulation cascade is response to vascular injury
[66]. This coagulation response also helps establish a fibrin based provisional matrix at the injury
site that provides structural and biochemical support for wound healing. Due to its ability to
enhance cell migration, fibrin has been explored for tissue engineering applications [68]. As a
result, fibrin has been used to study bone, cartilage, skin, nerve, and spinal cord regeneration [69].
Polysaccharides are macromolecules that consist of monosaccharides linked by oglycosidic bonds that form branched and linear structures [54]. Polysaccharides include chitosan,
alginate, amylose, cellulose, hyaluronic acid, and chondroitin sulfate. Glycosaminoglycans, such
as hyaluronic acid and chondroitin sulfate, are polysaccharides naturally found in the ECM that
also have excellent biocompatibility and bioactivity [11]. Using polysaccharides for tissue
engineering is highly advantageous since they are naturally found in the ECM and contribute to
cell signaling and growth [70]. Therefore, polysaccharides are easily recognized in the biological
environment and have both high biocompatibility and bioactivity which makes them promising
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materials for the tissue engineering field.
Chitosan is a cationic polymer derived from chitin found in the shell of crustaceans that
has shown high biocompatibility, ease of scaffold fabrication, and promise for tissue engineering
applications in skin, bone, cartilage, and vascular graft regeneration [66]. Chitosan is composed of
N-acetyl-glucosamine and N-glucosamine units and it is obtained through the alkaline
deacetylation of chitin, a linear polymer made of N-acetyl-glucosamine. Once the degree of
deacetylation (DD) of chitin exceeds 50%, the polymer is called chitosan. Chitosan is soluble in
dilute acidic conditions, such as in acetic acid solutions, under which its amino groups protonate
[71]. Chitosan can be ionically crosslinked, form polyelectrolyte complexes (PEC), or be
covalently crosslinked, which allow for pH neutralization and enhanced mechanical properties.
PECs form once the cationic chitosan is combined with a negatively charged polymer, such as
alginate, to form an ionic network [72]. Chitosan is a biodegradable material as it can be degraded
by human enzymes, such as lysozyme. Chitosan has multiple hydroxyl and amino function groups
that provide sites for chemical modifications. Therefore, many research groups have explored
attaching biomolecules to chitosan by covalent bonding, ionic bonding, or adsorption.
Alginate is brown algae derived anionic polysaccharide that has been used in the form of
hydrogels, beads, and scaffolds for tissue engineering applications due to its pro-angiogenic and
regenerative properties [73]. The molecular weight of alginate can range from 50 kDa to 100,000
kDa. Alginates are composed of (1,4)-linked -D-mannuronic acid (M) and -L-guluronic acid
(G) units within homopolymer blocks of similar (i.e. MMMM, GGGG) or alternating sections (i.e.
MGMG) [73]. The amounts of similar or alternating blocks is dependent upon the source of the
alginate. G blocks are typically stiffer than M blocks due to intramolecular bonding between the
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carboxyl and hydroxyl groups, therefore alternating these blocks increases the alginate solubility.
A common crosslinking technique for alginate, called ionic crosslinking, involves using divalent
cations (Ca2+ or Ba2+) to form bonds between carboxylic groups of neighboring G units.
Alginate stiffness changes with respect to composition following the trends: MG < MM <
GG, while elasticity increases with GG < MM < MG. Therefore, alginate properties can be tuned
by changing the M:G ratio, crosslinking method, and molecular weight [37]. While alginate is a
natural polymer, it is foreign to mammalian cells and cannot be broken down by enzymes in vivo.
In the case of ionically crosslinked alginate, degradation can occur by the release of crosslinking
divalent ions into the surrounding medium for monovalent ions. As calcium ions are released,
carboxyl anion repulsion further accelerates the swelling and erosion of the alginate chains [74].
Therefore, in vivo control of alginate degradation is poor. Additionally, mammalian cells do not
naturally adhere to alginate and this material is relatively biologically inert. In order to improve
cell adhesion, ECM proteins and peptides (such as collagen and RGD peptides) can be physically
or chemically attached to alginate [28, 29].

Figure 6.Various natural polymers used for tissue engineering applications [8].

Both chitosan and alginate are polymers that readily absorb excess fluid from their
environment. Therefore, scaffolds made of either material can be more prone to degradation within
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the physiological environment through bulk erosion. Forming PECs of chitosan and alginate
allows for superior mechanical properties due to a lower degree of swelling. While chitosan was
effectively degraded by lysozymes, the effect of these enzymes on the degradation of CA
complexes was negligible due to strong interactions between the chitosan and alginate polymeric
chains for almost 2.5 hours [77]. The stability of chitosan alginate PECs are influenced by charge
ratio, molecular weight, ionic strength, pH, and mixing order [78]. Since polymer ratios can change
the rate of biodegradation, chitosan alginate polymer blends have high potential for tissue
engineering applications.
Chitosan-Alginate Materials
Polysaccharide biomaterials are of high relevance to the tissue engineering field since they
are naturally derived and have a chemical structure that closely mimics that of glycosaminoglycans
in native ECM. When cationic chitosan and anionic alginate are blended together in solution, they
can form PECs due to electrostatic interactions. Chitosan-Alginate (CA) PEC formation is
dependent on solution pH, polymer molecular weight, and alginate to chitosan ratio. While alginate
is naturally non-adhesive to mammalian cells, CA materials exhibit better cell adhesion due to the
ability of positively charged chitosan to adsorb serum proteins. Therefore, CA materials combine
the advantages of its independent polymer components while reducing the drawbacks.
CA materials can be processed to induce a phase separation that gives a porous
microstructure to ensure cell attachment, tissue growth, and allow the flow of nutrients. This can
be accomplished by freeze casting and freeze drying CA solutions. Scaffold porosity is dependent
on many processing parameters, including freezing temperature, molecular weight of polymer, and
polymer solution concentrations. Solution viscosity, which is dependent on concentration, has
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been found to be the main parameter regulating pore structure and scaffold mechanical properties
[79]. These parameters influence the shape and size of ice crystals that form scaffold pores after
freeze drying. CA scaffolds have been previously fabricated to yield pore sizes from 100 to 300
µm [1]. Additionally, CA scaffolds have been demonstrated to have superior mechanical properties
than chitosan scaffolds due to strong ionic interactions between chitosan and alginate to form
PECs.
CA biomaterials investigated for tissue engineering applications with in vitro studies have
been shown to promote cell adhesion and proliferation for cartilage, bone, and embryonic stem
cell (ESC) cultures [79]. CA scaffolds demonstrated for bone tissue engineering with osteoblasts
showed that cells attached to the scaffold, proliferated, and deposited calcified matrix. Also,
calcium deposits on CA scaffolds were observed starting the fourth week after implantation [1].
CA scaffolds were also investigated for cartilage tissue engineering with HTB-94 cells, where cell
proliferation was found to be faster in CA scaffolds than in pure chitosan scaffolds. Additionally,
HTB-94 cells remained spherical in the CA scaffolds while showing an elongated morphology in
the chitosan scaffolds [80]. CA scaffolds have also been investigated for culturing human
embryonic stem cells (hESCS) and were demonstrated to support cell renewal without conditioned
medium or feeder cell support [81].
In addition to in vitro cell culture studies, CA scaffolds have been demonstrated to support
functional bone tissue engineering in vivo with a critical size calvarial defect model. CA scaffolds
were found to support undifferentiated MSCs in culture for 14 days in vitro with a spherical
morphology. In vivo tests showed that the best defect closure was obtained for CA scaffolds with
bone morphogenetic protein-2 (BMP-2) treatment [2].
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Previous studies with CA scaffolds have demonstrated support of stem cell self-renewal
while maintaining stem cells undifferentiated but only one CA scaffold composition (4 wt% CA)
was investigated. By varying the CA scaffold concentration (2-6 wt% CA), we can evaluate if
substrate stiffness guides BMSC differentiation into either adipogenic or osteogenic lineages.
Therefore, this study will examine cell-material interactions in CA scaffolds and determine if
mechanotransductive signaling from varying substrate stiffness can overcome BMSC stemness to
support differentiation.
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CHAPTER 3: METHODOLOGY
Materials
Chitosan (practical grade, >75% deacetylated, MW=190,000 - 375,000 Da), alginate (from
brown algae), dexamethasone (DEX), isobutylmethylxanthine (IBMX), indomethacin (IM), glycerolphosphate (BGP), L-ascorbic acid 2-phosphate (LAA) were purchased from SigmaAldrich (St. Louis, MO). Alpha minimum essential medium (-MEM), penicillin/streptomycin
(P/S), L-glutamine (L-glut), Dulbecco’s phosphate buffered saline (D-PBS), trypsin-EDTA
(0.25%), Alamar Blue solution, CellTracker chloromethyl-benzamidodialkylcarbocyanine (CMDiI) and Hoescht 33342 stains were purchased from Fisher Scientific (Waltham, MA). Fetal
bovine serum (FBS) was purchased from Atlanta Biologicals (Atlanta, GA). Accumax was
purchased from Innovative Cell Technologies (San Diego, CA). BMSCs from seven donors were
purchased from RoosterBio (Frederick, MD). Additional information regarding BMSC donor
gender and age can be found in Table 1.
Table 1. BMSC donor information.
Donor
12
16
37
49
55
70
81

Sex
M
F
M
M
M
F
M
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Age
33
29
43
23
22
20
25

CA scaffold synthesis
2, 4, and 6 wt% CA scaffolds were prepared according to previously published methods
[1, 2]. The chitosan and alginate solutions were prepared separately and equal amounts of chitosan
and alginate were used to prepare the CA solutions. To synthesize a 4 wt% CA scaffold, 4 wt%
chitosan and 4 wt% alginate solutions were prepared. A 4 wt% chitosan solution was prepared in
1 wt% acetic acid and a 4 wt% alginate solution was prepared in DI water. Both solutions were
prepared by dissolving the raw material powders in their respective solvents and mixing three
times with a Thinky mixer (Thinky Corporation, Laguna Hills, CA) at 2000 rpm for several
minutes. Excess heat in the mixer was dissipated between samples to keep mixing temperatures
consistent in all solutions. Both solutions were aged overnight and mixed several times in a Thinky
mixer. The 4 wt% chitosan solution with higher viscosity was added to the 4 wt% alginate solution
with lower viscosity and the combined 4 wt% CA solution was mixed several times with a Thinky
mixer at 2000 rpm. This step helps the formation of CA PECs. After mixing the solutions, the 4
wt% CA solution was casted in 12-well plates and its pH was measured. CA samples were
refrigerated at 4°C for 1 hour, frozen at -20 °C overnight, and lyophilized for 2 days. CA scaffolds
were then sectioned at 2 mm thickness, crosslinked in 0.2 M CaCl2 for 15 minutes under vacuum,
and washed three times with DI water. Sterilization was performed by soaking scaffolds in 70%
ethanol solution for 30 minutes under vacuum, washing three times with D-PBS, and washing
overnight with D-PBS in the shaker plate. The CA method was adapted to produce different
scaffold properties by varying the polymer and acetic acid concentrations to yield 2, 4, and 6 wt%
CA scaffolds as can be observed in Tables 2 and 3.
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Table 2. 2, 4, and 6 wt% Alginate concentrations in DI water.
Wt%

Alginate (g)

DI water (g)

2

2.084

100

4

4.167

100

6

6.25

100

Table 3. 2, 4, and 6 wt% Chitosan concentrations in acetic acid solutions.
Wt%

Chitosan (g)

Acetic acid (g)

DI water (g)

2

2.084

0.5

99.5

4

4.167

1.0

99.0

6

6.25

1.5

98.5

Scanning Electron Microscopy
CA scaffold microstructure was analyzed with scanning electron microscopy (SEM).
Samples were sputter coated with palladium-gold (Pd-Au) before being imaged with a JSM 6480
(JEOL, Tokyo, Japan). Average pore sizes were determined by drawing five equally spaced line
segments on the SEM micrographs at 50× magnification, counting the number of pores intersecting
each line, and finding the ratio of intercepts to line length. This method was adapted from the
ASTM E112-13 standard method for determining average grain size [82].
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Mechanical Testing
The stiffness of the scaffolds were assessed in both wet and dry conditions at room
temperature using the AGS-X mechanical tester (Shimadzu, Japan). The CA scaffolds were cut
into 10 mm x 10 mm x 10 mm cubes and compressed at a rate of 0.4 mm/min using a 500 N load
cell until reaching 40% of the initial height. Scaffolds were crosslinked with 0.2 M CaCl2, washed
with D-PBS, and stored in D-PBS prior to mechanical compression testing for wet conditions.
Young’s moduli were calculated from the slopes of the linear regions of the stress–strain curves.
Fourier Transform Infrared Spectroscopy
PEC formation was assessed in the CA scaffold array with Fourier Transform Infrared
(FTIR) Spectroscopy. Freeze dried scaffolds were ground with potassium bromide into a fine
powder. The mixed powder was compressed to a transparent pellet of 0.8-1 mm thickness with
the Quick Press KBr Pellet Kit (International Crystal Lab, Garfield, NJ). Scaffolds were analyzed
with FTIR (Nexus 870, Thermo Scientific, Waltham, MA) with 300 scans at 8 cm-1 resolution.
Cell culture
BMSCs were expanded for six days in T-150 flasks (Corning, Waltham, MA). Cultures
were maintained in fully supplemented -MEM with 16.5% FBS, 1% P/S, and 1% L-glut at 37 °C
and 5% CO2 in a fully humidified incubator. BMSCs were detached with 0.25% Trypsin-EDTA.
Prior to seeding, cell pellets were resuspended in D-PBS at 1×106 cell/mL. Then, cell solutions
were stained with CellTracker CM-DiI stain (5 L/mL), incubated at 37 °C for 5 minutes, 4 °C for
15 minutes, and washed three times with D-PBS. Afterwards, cell solutions were stained with
Hoescht 33342 stain (1 L/mL), incubated at room temperature for 20 minutes, and washed three
times with D-PBS. Cells were resuspended in media at 2×106 cell/mL concentration and seeded
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dropwise onto damp CA scaffolds in 12-well plates at 200,000 cells per scaffold with 100 L of
cell suspension. Scaffolds were incubated for 2 hours after cell seeding before 1.5 mL of cell media
were added to the wells. For 2D samples, 500 µL of cell solution (100,000 cells) and 1 mL of cell
media were added to the 12-well plate wells. Media was replaced at least every 2 days. The cultures
were allowed to proliferate for 14 days, then the cultures were switched to adipogenic or osteogenic
media and cultured for an additional 28 days to induce differentiation. Adipogenic media contained
0.5 M DEX, 0.5 M IBMX, and 50 M IM in fully supplemented -MEM. Osteogenic media
contained 10 nM DEX, 20 mM BGP, and 50 M LAA in fully supplemented -MEM.
Cell proliferation analysis
The Alamar Blue assay was used to assess cell proliferation in CA scaffolds and 2D wells
at 2, 7, and 14 day timepoints following the manufacturer’s protocols. 1.5 mL of Alamar Blue
solution (10 v/v% in media) was added to each sample well and incubated for 2.5 hours.
Afterwards, the Alamar Blue solutions were transferred to a black-bottom 96-well plate and was
read with fluorescence at 560 nm excitation, 590 nm emission with a Cytation5 imaging multimode reader (Biotek, Winooski, VT). Samples were washed once with D-PBS and 1.5 mL of cell
culture medium was added. Cell numbers were calculated from standard curves with known cell
numbers for each cell donor.
Cell imaging
Live cell fluorescence imaging was performed to observe cell morphology and nuclei with
CM-DiI and Hoescht 33342 stains at the 3, 7, and 14 day time points. Samples were imaged with
the Cytation5 cell imaging multi-mode reader (Biotek, Winooski, VT) at 4× and 20×
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magnifications with DAPI and RFP filters. Brightfield images were also obtained for all samples
at both magnifications.
Alizarin Red and Oil Red O staining
Scaffolds and 2D samples were fixed with 3.7% formaldehyde solution for 1 hour and
washed three times with D-PBS prior to staining. Samples treated with adipogenic differentiation
media were immersed with 60% isopropanol for 10 minutes, stained with Oil Red O staining
solution for 15 minutes, and washed three times with D-PBS. Samples treated with osteogenic
differentiation media were processed to prepare slides for histology analysis using the Leica ASP
300S tissue processor, Leica EG1150 C tissue embedder, and Leica RM 2235 microtome (Wetzlar,
Germany). Histology samples were cut into 16 µm sections, mounted on slides, dewaxed,
rehydrated, stained with Alizarin Red staining solution for 10 minutes, and washed three times
with DI water. All samples were imaged using the Cytation5 imaging multi-mode reader.
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CHAPTER 4: RESULTS AND DISCUSSION
Scanning Electron Microscopy
Scaffolds of 2, 4, and 6 wt% CA concentrations were produced successfully and were
stable in aqueous conditions after crosslinking. SEM images of all CA scaffold compositions (2,
4, 6 wt%) were obtained at two different magnifications (50, 200) in order to better assess the
pore structure changes resulting from variations in composition. CA scaffolds yielded an
interconnected porous structure as a result of the sublimation of ice from CA solutions during
lyophilization. Higher CA scaffold concentrations (4, 6 wt%) have smaller pore structures than
lower CA scaffold concentrations (2 wt%), as can be observed in Figure 7.

Figure 7. SEM images of 2, 4, 6 wt% CA scaffolds taken at 50 and 200 magnifications.

29

Porosity variations among the CA scaffold array compositions were also quantitatively
assessed by calculating the average pore sizes for all CA scaffold compositions. Our approach was
adapted from the ASTM E112-13 standard method for determining average grain sizes [82]. The
average pore size values for 2, 4, and 6 wt% CA scaffolds can be found in Table 4. As expected,
average pore sizes decrease with increasing CA scaffold concentrations. This occurs as increasing
CA concentrations with higher polymer densities reduce the size of ice crystals formed, thereby
giving an overall smaller microporous structure.

Table 4. CA scaffold average pore sizes.
Scaffolds

Average Pore Size (µm)

Standard Deviation

2% CA

233.3

23.7

4% CA

208.2

37.9

6% CA

146

17.8

Mechanical Testing
The elastic modulus of all CA scaffold compositions (2, 4, 6 wt%) was determined with
compression mechanical testing (Figure 8). Besides measuring the elastic modulus of the CA
scaffolds after lyophilization (dry condition), the elastic modulus of CA scaffolds was also tested
under wet conditions. Samples prepared for the wet condition were crosslinked, sterilized, and
washed overnight prior to compression testing. The elastic modulus of CA scaffolds in the wet
condition was relevant since it better resembled the mechanical properties BMSCs are exposed
to during in vitro cultures.
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Figure 8. CA scaffold compression mechanical testing under dry (A) and wet (B) conditions.

The mechanical properties of CA scaffolds in dry conditions were one to two orders of
magnitudes higher than CA scaffolds in wet conditions. This decrease in Young’s modulus has
also been observed in wet conditions compared to dry conditions by other research groups in a
variety of polymer substrates [83]. This type of behavior is mainly due to the plasticizing effect of
water in the CA scaffolds, which allows CA polymer chain fibers a greater freedom of motion.
Due to higher porosity size at the lower CA scaffold concentrations, this plasticizing effect yields
a lower elastic modulus for 2 wt% CA scaffolds than 4 and 6 wt% CA scaffolds.
Measuring the differences in CA scaffold stiffness under wet conditions (that mimic in
vitro conditions) is key to understanding BMSC behavior, since BMSCs grow in the wet
environment during cell culture. Moreover, it has been demonstrated that BMSCs commit to
specific lineages with high sensitivity to matrix stiffness [75]. Substrate elasticity also affects other
important cellular processes such as cell adhesion, growth, proliferation, and differentiation [84].
CA scaffold elasticity values in the dry condition (0.22–5.34 kPa) best match the elastic
modulus for brain tissue (0.1–1 kPa) with the 2 wt% CA scaffold stiffness (0.22 kPa). On the other
hand, 4 and 6 wt% CA scaffolds in the dry condition (3.14 and 5.34 kPa) have stiffnesses values
between the upper limit for brain and lower limit for muscle tissue (1–8 kPa). CA scaffold elasticity
values in the wet condition (21.1–47.3 Pa) are lower than typical brain tissue stiffness
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measurements. While previous studies have demonstrated 2D materials with similar stiffnesses to
native tissue for BMSC differentiation into multiple lineages, the effects of 3D porous
microenvironment stiffness variations on BMSC cell fate have not been established. Therefore,
this study will help elucidate the relationship of CA scaffolds stiffness and BMSC differentiation.
Fourier Transform Infrared Spectroscopy
FTIR was performed for all CA scaffold compositions and in chitosan and alginate only
scaffolds in order to confirm PEC formation (Figure 9). The characteristic peak in alginate for the
carboxylic acid group can be observed at 1600 cm-1. The characteristic peaks in chitosan for the
amide group and primary amine N-H bending were observed at 1650 and 1590 cm-1 respectively.
The CA scaffold PEC formation was demonstrated by the merging of the characteristic peaks for
chitosan and alginate to form a broader peak at 1630 cm-1. The characteristic peak at 1630 cm-1
was observed in the 2, 4, and 6 wt% CA scaffolds, indicating PEC formation at all concentrations.

Figure 9. FTIR spectra of 2, 4, 6 wt% CA, chitosan, and alginate scaffolds.
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Preliminary Study: Evaluation of Proliferation for Multiple BMSC Donors
Prior to starting the BMSC differentiation study, a preliminary trial testing the proliferation
of 7 BMSC donors within the 4 wt% CA scaffold composition was carried out by using the Alamar
Blue proliferation assay. All BMSC donors increased in cell number with increasing timepoints
and BMSC donor 81 reached the highest cell number in the 4 wt% CA scaffold, as can be observed
in Figure 10.

Figure 10. BMSC Multiple Donor proliferation study in 4 wt% CA scaffolds.

Additionally, all BMSC donors formed cell spheroids in the 4 wt% CA scaffolds as can be
observed in Figure 11. Spheroid formation could be attributed to the fact that CA scaffolds are
polysaccharide-based and lack matrix proteins to facilitate cell adhesion and cell spreading.
Donors 12, 37, and 81 formed cell spheroids of similar size.
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Figure 11. BMSC donors cluster into cell spheroids in 4 wt% CA scaffolds at day 7 of proliferation.

Spheroid size also varied with time for all CA scaffold compositions, with the greatest size
of spheroids being observed at day 3 and decreasing afterwards, as can be observed in Figure 12.
It is possible that at later timepoints, BMSCs begin to migrate within the scaffolds, thereby
decreasing spheroid size.
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Figure 12. BMSC donor 12 in 4 wt% CA scaffolds at days 1, 3, and 7. Cell nuclei were observed with the
Hoescht live fluorescent stain.

This preliminary study helped us evaluate the proliferation of the BMSC donors and also
their cell morphology response to 2, 4, and 6 wt% CA scaffolds. For the rest of this thesis, three
BMSC donors were chosen based on their proliferation capacity and CA scaffolds response. While
donors 16, 70, and 81 showed the greatest proliferation, cell morphology response to the CA
scaffolds was not consistent for donors 16 and 70. Donors 12 and 37 were the next two BMSC
donors with highest proliferation capacity. Additionally, they showed a similar and consistent
morphology response to the CA scaffolds as donor 81, with BMSC clustering of comparable size.
Therefore, donors 12, 37, and 81 were chosen for this study due to their proliferation capacity and
similar cell morphology response to the CA scaffolds.

Table 5. Three selected BMSC donors for differentiation study.
Donor
12
81
37

Sex
M
M
M

Age
33
25
43

Cell proliferation
In order to assess the proliferation of BMSCs in this study, we performed the Alamar Blue
assay in all CA scaffold compositions and 2D substrates at days 2, 7, and 14 of proliferation. Cell
numbers are highest in 2D samples than in any scaffold composition at all timepoints. This was
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expected since tissue culture plates are treated to promote cell adhesion and proliferation, while
CA scaffolds lack adhesion proteins and therefore can lower BMSC proliferation rates.
As can be observed in Figure 13, the main trend among both scaffolds and 2D samples is
an increase in cell number, especially apparent at the 14 day timepoint. Among the different
scaffold groups, the 2% CA scaffold shows the greatest increase in cell numbers reaching close to
400,000 cells at the fourteen day timepoint. Additionally, donor 81 yields the greatest cell numbers
among all BMSC donors after the day 3 timepoint.
The Alamar Blue proliferation assay gave us important insights regarding differences in
proliferation within BMSC donors and materials. It is noticeable that there are differences in
proliferation capacity between BMSC donors since all samples were seeded with the same cell
concentration but yielded different cell numbers at later timepoints. Even when donors 12 and 81
yielded similar cell numbers at the day 3 timepoint in 2% CA and 6% CA samples, this trend was
not maintained. Donor 81 yielded much higher cell numbers at later timepoints. Therefore, the
Alamar Blue data indicates that there are inherent differences in the proliferation capacity among
BMSC donors and confirms our results from the preliminary proliferation study of multiple BMSC
donors. Additionally, BMSCs in the 2% CA scaffold reached higher cell numbers than in the 4%
CA and 6% CA scaffold compositions. This indicates that there may be a difference in BMSC
proliferation capacity with different scaffold stiffnesses.

36

Figure 13. Alamar Blue data for BMSCs in 2, 4, 6 wt% CA and 2D substrates at days 2, 7, and 14.

Cell Imaging
Cell imaging was performed with the Hoescht 33342 and DiI live fluorescent stains. The
Hoescht dye identified the cell nuclei, while the DiI dye helped visualize the cell morphology. At
day 3 of proliferation, all BMSC donors clustered into spheroids in the 2, 4, and 6 wt% CA
scaffolds while remaining elongated in 2D substrates, as can be observed in Figure 14 which shows
overlaid images of both live fluorescent dyes. Bigger spheroids were observed at the higher CA
scaffold concentrations (4, 6 wt% CA), while smaller spheroids were seen at the lower CA scaffold
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concentrations (2 wt% CA). The BMSC clustering response within the CA scaffolds may be due
to its polysaccharide based chemistry and absence of adhesion proteins.

Figure 14. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 3 of
proliferation were stained Hoechst and DiI live fluorescent dyes.

Similar trends regarding BMSC spheroid size and CA scaffold composition were observed
at the 7 and 14 day timepoint as can be observed in Figures 15 and 16, with higher spheroid size
corresponding to the stiffer substrates and vice versa. Additionally, cells in 2D substrates remained
elongated at all timepoints and increased in confluency. It was also observed that the DiI staining
intensity decreased with increasing timepoints, specially in BMSCs seeded on 2D substrates. This
occurs since the DiI stain binds to the cell membrane and therefore decreases in concentration as
cells undergo division cycles at later timepoints.
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Figure 15. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 7 of
proliferation were stained Hoechst and DiI live fluorescent dyes.

39

Figure 16. BMSC donors 12, 37, and 81 in 2, 4, 6 wt% CA scaffolds and 2D substrates at day 14 of
proliferation were stained Hoechst and DiI live fluorescent dyes.

Spheroid size also varied at different timepoints, as can be seen in Figure 17 for BMSC
donor 81 in 2, 4, and 6 wt% CA scaffold at days 3, 7, and 14 of proliferation. The greatest spheroid
size was observed at the day 3 timepoint and decreased afterward. These observations were
consistent with the preliminary results from the multiple donor BMSC study in Figure 10. We
believe decreasing spheroid size could be due to increased cell migration out of the spheroids into
the scaffold.
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Figure 17. BMSC Donor 81 in 2, 4, 6 wt% CA scaffolds at 3, 7, 14 day timepoints of proliferation.

Oil Red O and Alizarin Red Staining
Oil Red O
BMSCs cultured on 2D substrates with adipogenic differentiation medium were stained
with Oil Red O dye after 14 and 28 days of differentiation. As can be observed in Figure 18 and
19, the Oil Red O staining solution stains lipid droplets red indicating adipogenic differentiation
in BMSCs. Therefore, adipogenic differentiation was achieved in this study among all BMSC
donors in the 2D substrates at 14 and 28 days of differentiation.
While adipogenic differentiation occurred among all BMSC donors, the extent of
differentiation varied. As can be observed in the lower magnification images of Figures 18 and 19,
donor 12 had less positive Oil Red O staining than donor 37 and, similarly, donor 37 had less
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positive staining than donor 81. Additionally, the size of the BMSC fat droplets was higher for
donor 81 than for donors 12 or 37. Therefore it is not only important to study a single BMSC donor
response to a specific substrate or scaffold, but also to look at multiple donor responses since they
can give varied results even as control (2D) groups.

Figure 18. Oil Red O staining on BMSC donors in 2D substrates at 14 days of adipogenic differentiation.

Besides donor variation, differences in the extent of differentiation were also observed at
different timepoints. Lipid droplets deposited by BMSCs undergoing adipogenic differentiation
are larger in size at the day 28 differentiation timepoint, as can be observed in Figure 19. Greater
amounts of lipid deposition by adipocytes at day 28 of differentiation indicate a greater extent of
adipogenesis.
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Figure 19. Oil Red O staining on BMSC donors in 2D substrates at 28 days of adipogenic differentiation.

BMSCs cultured in 2, 4, and 6 wt% CA scaffolds under adipogenic differentiation medium
were stained with Oil Red O dye after 14 and 28 days of differentiation. Higher magnification
images from the 14 and 28 days of differentiation staining can be seen in Figures 20 and 21
respectively, where lipid droplets are stained red in all CA compositions and BMSC donors. Yet,
there is a clear distinction in the extent of adipogenic differentiation between materials and donors.
Lipid droplets are larger in size in 4 wt% CA and 6 wt% CA materials, while smaller in 2 wt% CA
materials. Additionally, donors 37 and 81 showed the largest size of lipid formation which
indicates a higher extent of adipogenic differentiation. Overview images of the CA scaffolds for
both timepoints are shown in Figures 22 and 23. These images demonstrate the sparse positive
staining indicating that higher cell numbers may need to be seeded to support robust adipogenesis.
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Figure 20. Oil Red O staining in 2, 4, 6% CA scaffolds at 14 days of adipogenic differentiation.
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Figure 21. Oil Red O staining in 2, 4, 6% CA scaffolds at 28 days of adipogenic differentiation.
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Figure 22. Overview images of Oil Red O staining in 2, 4, 6 wt% CA scaffolds at 14 days of
differentiation.

Figure 23. Overview images of Oil Red O staining in 2, 4, 6 wt% CA scaffolds at 28 days of
differentiation.
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Alizarin Red
BMSCs cultured on 2D substrates with osteogenic differentiation medium were stained
with Alizarin Red dye after 14 and 28 days of differentiation. As can be observed in Figure 24 and
25, the Alizarin Red solution stains calcium deposits in the matrix indicating osteogenic
differentiation in BMSCs. Therefore, osteogenic differentiation was achieved in this study among
all BMSC donors in the 2D substrates at 14 and 28 days of differentiation.
While osteogenic differentiation occurred among all BMSC donors, the extent of
differentiation varied. As can be observed in the overview images of Figures 25, donor 37 showed
a greater extent of osteogenic differentiation than donors 12 and 81. Additionally, the extent of
osteogenic differentiation increased from day 14 to day 28.

Figure 24. Alizarin Red staining on BMSC donors in 2D at 14 days of osteogenic differentiation.
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Figure 25. Alizarin Red staining on BMSC donors in 2D at 28 days of osteogenic differentiation.

BMSC samples cultured in 2, 4, and 6 wt% CA scaffolds under osteogenic differentiation
medium were stained with Alizarin Red dye after 14 and 28 days of differentiation. In Figure 26,
we can observe overview images for 2, 4, and 6 wt% CA samples at 14 days of osteogenic
differentiation media treatment. The positive red stain indicates osteogenic differentiation among
all donors and CA scaffold samples. Moreover, the darker spots indicate bone nodule formation
due to matrix mineralization. In day 14 samples, matrix mineralization was higher for samples in
stiffer substrates (4, 6 wt% CA) in comparison to softer substrates (2 wt% CA).
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Figure 26. BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with Alizarin Red after 14
days of osteogenic differentiation.
BMSC samples at 28 days of osteogenic differentiation were also processed for histology
and stained with Alizarin Red solution to analyze the extent of mineralization as can be observed
in Figure 27. Similarly to the day 14 differentiation results, all scaffold samples and BMSC donors
stained positively for osteogenic differentiation with Alizarin Red. 4 wt% CA and 6 wt% CA
samples exhibited greater matrix mineralization than 2 wt% CA samples indicated by bone nodule
formation. These results support our initial hypothesis, where stiffer substrates support greater
BMSC osteogenic differentiation and matrix mineralization. Higher magnification images for both
days 14 and 28 of osteogenic differentiation can be found in Figures 28 and 29, which more clearly
show nodule formation from calcium deposits in the scaffold. Greater mineralization at higher CA
scaffold stiffnesses supports that BMSC osteogenic differentiation is influenced by substrate
mechanical properties and that cell material interactions guide BMSC cell fate.
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Figure 27. BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with Alizarin Red after 28 days of
osteogenic differentiation.

Figure 28. High magnification images of BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with
Alizarin Red after 14 days of osteogenic differentiation.
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Figure 29. High magnification images of BMSC donors in 2, 4, 6 wt% CA scaffolds were stained with
Alizarin Red after 28 days of osteogenic differentiation
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CHAPTER 5: CONCLUSIONS
This thesis examined the effects of CA scaffold stiffness variation on BMSC adipogenic
and osteogenic differentiation. An array of CA scaffolds (2, 4, 6 wt% CA) was produced by
varying the polymer concentrations. CA scaffolds were fabricated by freeze casting and
lyophilization to yield an interconnected porous structure. The CA porous scaffold array had
different mechanical properties but the same chemical composition.
In order to characterize the CA scaffold properties, SEM, compression mechanical testing,
and FTIR were performed. SEM images and average pore size calculations demonstrated
decreasing pore sizes at higher CA scaffold concentrations. Compression mechanical testing
yielded higher elastic moduli values for higher CA scaffold concentrations in both dry and wet
conditions, with wet conditions giving values two orders of magnitude lower than dry conditions.
FTIR data demonstrated the formation of PECs at all CA scaffold compositions.
Three BMSC donors were seeded on the CA scaffold array to examine the cell response to
different scaffold stiffnesses and BMSC donor variation. The cell culture study included a 14 day
proliferation phase, followed by 28 days of differentiation under adipogenic or osteogenic
differentiation media. The Alamar Blue proliferation assay showed an increase in cell number at
the 14 day timepoint for all CA scaffold compositions and BMSC donors. BMSC donors 37 and
81 showed higher cell numbers than donor 12 at most timepoints in the alamar blue assay. BMSCs
formed spheroids in all CA scaffold compositions, with higher stiffnesses (4, 6 wt% CA)
promoting larger spheroid formation than lower stiffnesses (2 wt% CA). Spheroid size for all CA
scaffold compositions and BMSC donors decreased after day 3 of proliferation possibly due to cell
migration in the scaffold.
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After 28 days of adipogenic differentiation, BMSCs in CA scaffolds and 2D samples were
stained with Oil Red O dye to target lipid droplets indicating adipogenic commitment. In 2D
samples, the largest positive Oil Red O staining was observed for donor 81, followed by donors
37 and 12 respectively. In the CA scaffold array, the greatest Oil Red staining was observed for
donors 37 and 81 in the 4 and 6 wt% CA scaffolds.
While positive Oil Red O staining was observed for all scaffold compositions, more robust
differentiation was expected at the lower CA scaffold concentrations (2 wt% CA). Therefore this
study disproved our hypothesis for the adipogenic differentiation group. The polysaccharide
composition of the CA scaffolds likely contributed to the spheroid formation and influenced the
extent of differentiation. It can be noted that the largest adipogenic differentiation was observed in
scaffolds that yielded the largest cell clusters (4, 6 wt%).
The extent of osteogenic differentiation was also assessed for BMSCs in CA scaffolds and
2D samples with Alizarin Red dye to target calcium deposits indicating osteogenic differentiation.
In 2D samples, the largest Alizarin Red staining was observed for donor 37. Additionally, the
extent of osteogenic differentiation increased from day 14 to day 28 among all BMSC donors. In
the CA scaffolds, all compositions stained positively for osteogenic differentiation at both day 14
and day 28 of differentiation. Stiffer substrates (4, 6 wt% CA) exhibited greater mineralization
than softer substrates (2 wt% CA) indicated by matrix darkening, also called bone nodule
formation, surrounded by positive Alizarin Red staining. While all CA compositions and BMSC
donors supported osteogenic differentiation, scaffolds with higher stiffnesses showed a greater
extent of osteogenic differentiation indicated by matrix mineralization. Therefore, samples treated
for osteogenic differentiation supported our initial hypothesis that stiffer scaffold substrates would
further guide BMSCs towards osteogenic lineage differentiation.
53

For both adipogenic and osteogenic differentiation, the greatest extent of differentiation
occurred in the 4 and 6 wt% CA scaffolds relative to the 2 wt% CA scaffolds. These scaffold
compositions also formed the largest cell spheroids, which studies have associated with stemness
markers [85]. It is possible that 4 and 6 wt% CA scaffolds helped maintain BMSC stemness during
the proliferation phase indicated by the larger cell clusters, which could contribute to a greater
extent of differentiation. Further optimization of the CA scaffolds will be needed in order to
examine the effects of scaffold stiffness independently of the effects of polysaccharide chemistry
and spheroid formation on BMSC differentiation. Protein based coatings could be adsorbed onto
the CA scaffolds to enhance BMSC adhesion, proliferation, and differentiation, while changing
the cell morphology from a spherical to an elongated shape. Additionally, increasing scaffold cell
density could potentially yield more robust differentiation.
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APPENDIX A: BMSC DONOR 81 STANDARD CURVE FOR ALAMAR
BLUE ASSAY
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(A) List of intensity readings from the Alamar Blue assay at different cell numbers from 0 to 1.5
million. Blank readings were subtracted from these intensity values.
(B) Standard curve generated from the trendline of cell number and intensity values.
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APPENDIX B: OVERVIEW IMAGES OF BMSCS IN CA SCAFFOLD
SAMPLES AT DAYS 3, 7, AND 14 OF PROLIFERATION
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Day 3

DiI and Hoescht stains at day 3 of proliferation for BMSC donors seeded on 2, 4, 6 wt% CA
scaffolds.

Day 7

DiI and Hoescht stains at day 7 of proliferation for BMSC donors seeded on 2, 4, 6 wt% CA
scaffolds.
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Day 14

DiI and Hoescht stains at day 14 of proliferation for BMSC donors seeded on 2, 4, 6 wt% CA
scaffolds.
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APPENDIX C: ALIZARIN RED CONTROL STAINING OF 2, 4, 6 WT%
CA SCAFFOLDS WITHOUT BMSCS
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Control staining of Alizarin Red solution in 2, 4, 6 wt% CA scaffolds without BMSCs
crosslinked, sterilized, and processed for histology.
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